Cassava ends simufilam Alzheimer’s programme after second Phase III failure
While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.
While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.
What's Your Reaction?
